–์ Wˆ๊@Koichi FUKINO
œˆใˆ๕E•Ž่i•t‘ฎ‘ๆ“๑•a‰@”]_ŒoŠO‰ศj
œ‘ฒ‹ฦ‘ๅŠwE‘ๅŠw‰@@L“‡‘ๅŠwˆใŠw•”ˆใŠw‰ศi•ฝฌ6”NjE“๚–{ˆใ‰ศŠwˆใŠwŒค‹†‰ศi•ฝฌ12”Nj
œ—ฏŠwๆ Postdoctoral Fellow, Human Cancer Genetics Program, The Comprehensive Cancer Center, The Ohio State University, Ohio, USA.
œˆใŠw”ŽŽm
œ๊–ๅ•ช–์@ ”]Ž๎แ‡
œŠ‘ฎŠw‰๏@“๚–{”]_ŒoŠO‰ศŠw‰๏i๊–ๅˆใj/“๚–{ŠเŠw‰๏@
American Association for Cancer Research (Associate Member)@“™
œŽๅ‚ศŒค‹†ƒe[ƒ}@Ž๎แ‡‚ฬ•ชŽqถ•จŠwGGenome/Genetics•ช–์

@

‘ใ•\˜_•ถ

‘ใ•\˜_•ถi3‘่EยF”ิ†4,14,15j‚ฦ‚ป‚๊ˆศŠO‚ฬ‘S‚ฤ‚ฬ”ญ•\˜_•ถ
(1) Weber F, Fukino K, Villalona-Calero M, Eng C.
Limitations of single-strand conformation polymorphism analysis as a high-throughput method for the detection of EGFR mutations in the clinical setting.J Clin Oncol. 2005; 23: 5847-8.

(2) Weber F, Fukino K, Sawada T, Williams N, Sweet K, Brena RM, Plass C, Caldes T, Mutter GL, Villalona-Calero MA, Eng C.
Variability in organ-specific EGFR mutational spectra in tumour epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors. Br J Cancer. 2005; 92: 1922-6. 

(3) Fukino K, Terao T, Kojima T, Adachi K, Teramoto A.
Chronic subdural hematoma following dural metastasis of gastric cancer: measurement of pre- and postoperative cerebral blood flow with N-isopropyl-p-[123I]iodoamphetamine-case report. Neurol Med Chir (Tokyo). 2004;@44:@646-9.

(4) Fukino K, Shen L, Matsumoto S, Morrison CD, Mutter GL, Eng C.
Combined total genome loss of heterozygosity scan of breast cancer stroma and epithelium reveals multiplicity of stromal targets.@Cancer Res. 2004;64:7231-6.

(5) Fukino K, Yamada S, Ohta T, Takada K, Usui M.
Serial MR intensity changes of the posterior pituitary in patients with diabetes insipidus after transsphenoidal surgery for pituitary adenomas: report of two cases. Pituitary. 2003; 6: 215-9.

(6) Niibe Y, Karasawa K, Nakamura O, Shinoura N, Okamoto K, Yamada R, Fukino K, Tanaka Y. 
Survival benefit of stereotactic radiosurgery for metastatic brain tumors in patients with controlled primary lesions and no other distant metastases. Anticancer Res. 2003; 23: 4157-9.

(7) Yokota T, Tachizawa T, Fukino K, Teramoto A, Kouno J, Matsumoto K, Emi M.
A family with spinal anaplastic ependymoma: evidence of loss of chromosome 22q in tumor. J Hum Genet. 2003; 48: 598-602.

(8)
Yoshida S, Harada H, Nagai H, Fukino K, Teramoto A, Emi M.
Head-to-head juxtaposition of Fas-associated phosphatase-1 (FAP-1) and c-Jun NH2-terminal kinase 3 (JNK3) genes: genomic structure and seven polymorphisms of the FAP-1 gene. J Hum Genet. 2002; 47: 614-9.

(9)
Harada H, Kimura A, Fukino K, Yasunaga S, Nishi H, Emi M.
Genomic structure and eight novel exonic polymorphisms of the human N-cadherin gene. J Hum Genet. 2002; 47: 330-2.

(10)
Shimura T, Sugisaki Y, Fukino K, Node Y, Teramoto A, Kawamoto M.
Detection of Epstein-Barr virus DNA and expression of CD30 antigen in primary anaplastic diffuse large B-cell lymphoma of the brain. Brain Tumor Pathol. 2001; 18: 161-5.

(11)
Fukino K, Umeoka K, Kitamura T, Takahashi H, Teramoto A.
Cortical dysplasia with subcutaneous angioma and dilated dural venous sinuses. J Neuroradiol. 2001; 28. :127-9.

(12)
Yoshida S, Fukino K, Harada H, Nagai H, Imoto I, Inazawa J, Takahashi H, Teramoto A, Emi M.
The c-Jun NH2-terminal kinase3 (JNK3) gene: genomic structure, chromosomal assignment, and loss of expression in brain tumors. J Hum Genet. 2001; 46: 182-7.

(13)
Kojima T, Mizumura S, Kumita SI, Nakajo H, Kumazaki T, Kitamura T, Fukino K, Teramoto A.
Regional cerebral blood flow and vascular reserve in neuronal migration disorder assessed by Tc-99m hexamethylpropylene amineoxime SPECT with acetazolamide challenge. Clin Nucl Med. 2000; 25: 749-50.

(14)
Fukino K, Teramoto A, Adachi K, Takahashi H, Emi M.
A family with hydrocephalus as a complication of cerebellar hemangioblastoma: identification of Pro157Leu mutation in the VHL gene. J Hum Genet. 2000; 45: 47-51.

(15)
Fukino K, Kitamura Y, Sanno N, Teramoto A, Emi M.
Analysis of the MEN1 gene in sporadic pituitary adenomas from Japanese patients. Cancer Lett. 1999; 144: 85-92.

(16)
Minobe K, Bando K, Fukino K, Soma S, Kasumi F, Sakamoto G, Furukawa K, 
Higuchi K, Onda M, Nakamura Y, Emi M.
Somatic mutation of the PTEN/MMAC1 gene in breast cancers with microsatellite instability. Cancer Lett. 1999; 144: 9-16.

(17)
Emi M, Yoshimoto M, Sato T, Matsumoto S, Utada Y, Ito I, Minobe K, Iwase T, 
Katagiri T, Bando K, Akiyama F, Harada Y, Fukino K, Sakamoto G, Matsushima M, Iida A, Tada T, Saito H, Miki Y, Kasumi F, Nakamura Y.
Allelic loss at 1p34, 13q12, 17p13.3, and 17q21.1 correlates with poor postoperative prognosis in breast cancer. Genes Chromosomes Cancer. 1999; 26: 134-41.

(18)
Fukino K, Iido A, Teramoto A, Sakamoto G, Kasumi F, Nakamura Y, Emi M.
Frequent allelic loss at the TOC locus on 17q25.1 in primary breast cancers. Genes Chromosomes Cancer. 1999; 24: 345-50.

(19)
Kurose K, Bando K, Fukino K, Sugisaki Y, Araki T, Emi M.
Somatic mutations of the PTEN/MMAC1 gene in fifteen Japanese endometrial cancers: evidence for inactivation of both alleles. Jpn J Cancer Res. 1998; 89: 842-8.

(20)
–์ Wˆ๊A ]Œฉ [A ’†‘บ—S•ใ.
Šเ‚ฦˆโ“`Žqi“มW-—ีฐˆใ‚ษ•K—v‚ศˆโ“`ˆใŠwj. —ีฐˆใ 1999; 25: 1285-9.